GLABF (Gemina Laboratories) YoY EBITDA Growth: 62.50% (As of Oct. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Gemina Laboratories YoY EBITDA Growth?

Gemina Laboratories GLABF -27.59% YoY EBITDA Growth is 62.50% as of Oct. 2025. The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Gemina Laboratories's YoY EBITDA Growth for the quarter that ended in Oct. 2025 was 62.50%.

Gemina Laboratories's EBITDA per Share for the three months ended in Oct. 2025 was $-0.00.

Gemina Laboratories YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Gemina Laboratories's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gemina Laboratories YoY EBITDA Growth Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
YoY EBITDA Growth
0.00 0.00 6.41 28.77 30.77

Gemina Laboratories Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -30.00 25.00 55.56 62.50

Gemina Laboratories YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Gemina Laboratories's YoY EBITDA Growth for the fiscal year that ended in Jan. 2025 is calculated as:

YoY EBITDA Growth (A: Jan. 2025 )
=(EBITDA per Share (A: Jan. 2025 )-EBITDA per Share (A: Jan. 2024 ))/ | EBITDA per Share (A: Jan. 2024 ) |
=(-0.036--0.052)/ | -0.052 |
=30.77 %

Gemina Laboratories's YoY EBITDA Growth for the quarter that ended in Oct. 2025 is calculated as:

YoY EBITDA Growth (Q: Oct. 2025 )
=(EBITDA per Share (Q: Oct. 2025 )-EBITDA per Share (Q: Oct. 2024 )) / | EBITDA per Share (Q: Oct. 2024 )) |
=(-0.003--0.008)/ | -0.008 |
=62.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 62.50% mean?
Gemina Laboratories (GLABF) has a YoY EBITDA Growth of 62.50% as of Oct. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Gemina Laboratories and its competitors.
Is Gemina Laboratories' YoY EBITDA Growth too high?
Gemina Laboratories' current YoY EBITDA Growth is 62.50%.
How does Gemina Laboratories' YoY EBITDA Growth compare to VRTX and REGN?
Gemina Laboratories' YoY EBITDA Growth of 62.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Gemina Laboratories and its competitors. Gemina Laboratories's current YoY EBITDA Growth is 62.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gemina Laboratories stock overvalued right now?
Gemina Laboratories (GLABF) has a current YoY EBITDA Growth of 62.50%. The current YoY EBITDA Growth is 62.50%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Gemina Laboratories (GLABF), the current YoY EBITDA Growth is 62.50% as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gemina Laboratories Business Description

Address 3600 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.